Skip to records

Therapeutics

229Aging Biotech
100 of 229 records

NRG5051

Source date not recordedAnalyse record ↗

Investigational mitochondrial-permeability-transition inhibitor in Phase 1 for a development program focused on ALS and Parkinson's disease.

Modality
oral CNS-penetrant small-molecule NLRX1-mediated mitochondrial permeability transition pore inhibitor
Availability (US)
Phase 1; initial dosing in a randomized single- and multiple-ascending-dose study was announced January 8, 2026
Biomarkers
safety, tolerability, pharmacokinetics, neurofilament light, mitochondrial function, innate-immune activation, and target engagement
Hallmark targeted
mitochondrial dysfunction, chronic inflammation, loss of proteostasis
Kind
investigational drug
Clinical trials
NRG5051-101 — Phase 1 study, EU CT number 2025-523872-22-00